VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.

August 20, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Subject: Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we wish to inform that VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A., to commercialize YUVEZZITM, a proprietary ophthalmic product indicated for the treatment of Presbyopia in adults, in the European Union, the United Kingdom, Switzerland, Norway and Iceland. The details required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated January 30, 2026 (reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026), along with other applicable circulars, are set out in Annexure I. A press release regarding this arrangement is enclosed herewith. You are requested to kindly take the above on record. For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754) Encl.: a/a. LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com Annexure I Disclosure as per Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular. Sr. No. Particulars Details 1. Name of the entity(ies) with Visus Therapeutics, Inc., a Delaware corporation in U.S.A. (‘Visus’) whom agreement/JV is and VISUfarma B.V., the Netherlands, a wholly owned subsidiary signed of the Company (‘VISUfarma’). 2. Area of agreement/JV Exclusive License and Commercialization rights for YUVEZZITM in the European Union, the United Kingdom, Switzerland, Norway and Iceland (‘Licensed Territories’). 3. Domestic/international Across European Union, the United Kingdom, Switzerland, Norway and Iceland. 4. Share exchange ratio/JV ratio Not applicable. 5. Scope of business operation Exclusive rights to undertake regulatory activities, of agreement/JV commercialization, marketing, promotion, distribution and sale of YUVEZZI™ in the Licensed Territories. The Agreement is valid on a country-by-country basis in the Licensed Territories and will continue until the twentieth (20th) anniversary of the date of the first commercial sale of YUVEZZITM in the respective country (‘Initial Term’), subject to earlier termination in accordance with the terms of the Agreement. After the Initial Term, VISUfarma, at its sole discretion, will have the right to renew the Agreement in such country for one or more additional successive periods of five (5) years each. 6. Details of consideration paid/ The total potential consideration under the agreement is up to €75 received in agreement/JV million through to first commercial sales in the Territory, comprising (i) a €20 million strategic investment in the capital stock of Visus or its parent entity through a SAFE (Simple Agreement for Future Equity) instrument, which provides the right to receive capital stock of Visus or its parent entity upon the occurrence of specified equity financing or public listing events, and (ii) up to €55 million in regulatory and commercial milestone payments. In addition, the agreement provides for royalty payments based on net sales and sales milestone payments upon achievement of specified sales thresholds in the Licensed Territories, in accordance with the terms of the agreement. LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com The milestone payments are contingent upon achievement of specified regulatory submissions, approvals and other commercial milestones in respect of YUVEZZI™ in the Licensed Territories. 7. Significant terms and Same as stated in point (5) and (6) above. conditions of agreement/JV in brief Whether the acquisition The transaction does not fall within the ambit of related party 8. would fall within related party transaction. None of the promoter/promoter group/group transactions and whether the companies have any interest in the arrangement. promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” 9. Size of the entity(ies) Visus is a biopharmaceutical company focused on developing eyecare drugs to rejuvenate vision in the aging eye, affiliated with Tenpoint Therapeutics Holding Limited through a parent holding company structure. Visus lead commercial asset is YUVEZZI™, an FDA-approved treatment for Presbyopia. 10. Rationale and benefit This exclusive commercialization rights for YUVEZZI™ in Europe expected. will strengthen Lupin’s ophthalmology portfolio, expand its Specialty Business presence and create long-term growth opportunities in the Presbyopia treatment market across the Licensed Territories. LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com Press Release BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment Mumbai, India, Naples, FL, Netherlands, Amsterdam, London, UK, Warren, NJ, August 20, 2026: Global pharma major Lupin Limited (“Lupin”) today announced that VISUfarma B.V. (“VISUfarma”), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited (“Tenpoint”). This partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, a proprietary ophthalmic product indicated for the treatment of presbyopia in adults, in the European Union, the United Kingdom, Switzerland, Norway and Iceland (Licensed Territories). Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales. Vinita Gupta, Chief Executive Officer, Lupin, said, “We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy. Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets. The addition of YUVEZZI™ underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the Licensed Territories.” "This exciting partnership marks an important step for Tenpoint as we continue our work to make YUVEZZI™ available for the millions of patients with presbyopia and eye care professionals around the world,” said Henric Bjarke, Chief Executive Officer, Tenpoint. "Lupin’s strong commercial operations span major European markets, and its specialty ophthalmolog [Showing first 8,000 characters — download PDF for full document]